{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:02Z","timestamp":1786650002752,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bone metastasis (BM) is common in patients with lung cancer. Osteolysis is caused by increased osteoclast activity. Interleukin-20 (IL-20) and receptor activator of nuclear factor kappa-B ligand (RANKL) are crucial for osteoclast formation. Osteoprotegerin (OPG) inhibits a receptor activator of RANKL\/RANK signaling. The aims of this study were to analyze the serum levels of IL-20, OPG, and RANKL in patients with and without BM and to observe the effect of chemotherapy on these cytokines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A total 54 cases of pathologically confirmed lung adenocarcinoma (ADC) and 18 healthy individuals (Control) were enrolled in this study. Eligible patients were divided into three groups (18 patients per group): ADC without BM (ADC), ADC with BM (ADC + BM), and ADC with BM treated with chemotherapy (ADC + BM + Chemo). Serum IL-20, RANKL, and OPG levels were analyzed by enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Serum IL-20, RANKL, and OPG levels in ADC + BM patients were significantly elevated compared with that in the Control or ADC groups (both P &lt; 0.001). The serum cytokine levels were significantly lower following chemotherapy compared with that in patients who did not receive chemotherapy (P &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Serum IL-20, RANKL, and OPG levels increase in patients with lung cancer and BMs. Chemotherapy suppresses the elevation of these cytokines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.179085","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T05:29:41Z","timestamp":1458538181000},"page":"963-968","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis"],"prefix":"10.4103","volume":"12","author":[{"given":"Mingyang","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Traumatic Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Traumatic Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daping","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Traumatic Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Traumatic Orthopedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowu","family":"Luan","sequence":"additional","affiliation":[{"name":"Department Chemistry, Stony Brook University, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/1471-2407-14-416","article-title":"Inaugural bone metastases in non-small cell lung cancer: A specific prognostic entity?","volume":"14","author":"Deberne","year":"2014","journal-title":"BMC Cancer"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1096\/fj.04-1823fje","article-title":"Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement","volume":"19","author":"Roato","year":"2005","journal-title":"FASEB J"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1684\/bdc.2013.1724","article-title":"Biology of cancer metastasis","volume":"100","author":"Robert","year":"2013","journal-title":"Bull Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","article-title":"Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline","volume":"79","author":"Lutz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: Causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbm.a.32856","article-title":"Crosstalk of osteoblast and osteoclast precursors on mineralized collagen \u2013 Towards an in vitro model for bone remodeling","volume":"95","author":"Bernhardt","year":"2010","journal-title":"J Biomed Mater Res A"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1158\/1078-0432.CCR-13-1590","article-title":"Molecular mechanisms of bone metastasis and associated muscle weakness","volume":"20","author":"Waning","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"5090","DOI":"10.1038\/onc.2013.440","article-title":"A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer","volume":"33","author":"Luis-Ravelo","year":"2014","journal-title":"Oncogene"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1471-4906(01)02149-4","article-title":"The interleukin-10 family of cytokines","volume":"23","author":"Fickenscher","year":"2002","journal-title":"Trends Immunol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1359-6101(02)00012-6","article-title":"The family of IL-10-related cytokines and their receptors: Related, but to what extent?","volume":"13","author":"Kotenko","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S1471-4906(01)01985-8","article-title":"IL-10 and its homologs: Important immune mediators and emerging immunotherapeutic targets","volume":"22","author":"Volk","year":"2001","journal-title":"Trends Immunol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0092-8674(01)00187-8","article-title":"Interleukin 20: Discovery, receptor identification, and role in epidermal function","volume":"104","author":"Blumberg","year":"2001","journal-title":"Cell"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.167.7.3545","article-title":"Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types","volume":"167","author":"Dumoutier","year":"2001","journal-title":"J Immunol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"47517","DOI":"10.1074\/jbc.M205114200","article-title":"Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions","volume":"277","author":"Parrish-Novak","year":"2002","journal-title":"J Biol Chem"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1084\/jem.20102234","article-title":"Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss","volume":"208","author":"Hsu","year":"2011","journal-title":"J Exp Med"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/SPC.0b013e3282f335be","article-title":"RANKL signaling in bone physiology and cancer","volume":"1","author":"Dougall","year":"2007","journal-title":"Curr Opin Support Palliat Care"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S8756-3282(99)00214-8","article-title":"Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues","volume":"25","author":"Kartsogiannis","year":"1999","journal-title":"Bone"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S8756-3282(99)00121-0","article-title":"A novel molecular mechanism modulating osteoclast differentiation and function","volume":"25","author":"Yasuda","year":"1999","journal-title":"Bone"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ncponc0381","article-title":"Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis","volume":"3","author":"Blair","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jss.2012.03.018","article-title":"Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL\/OPG ratio to impair osteoclast differentiation","volume":"180","author":"Jin","year":"2013","journal-title":"J Surg Res"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.10943","article-title":"Serum levels of OPG, RANKL and RANKL\/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations","volume":"92","author":"Goranova-Marinova","year":"2007","journal-title":"Haematologica"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the international system for staging lung cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.bbrc.2005.05.122","article-title":"IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression","volume":"333","author":"Heuz\u00e9-Vourc'h","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.ejca.2011.04.012","article-title":"IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF","volume":"47","author":"Baird","year":"2011","journal-title":"Eur J Cancer"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"e58361","DOI":"10.1371\/journal.pone.0058361","article-title":"Differential expression of the RANKL\/RANK\/OPG system is associated with bone metastasis in human non-small cell lung cancer","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"issue":"Pt 4","key":"R29-20260109","first-page":"1537","article-title":"Scanning electron microscopy in bone pathology: Review of methods, potential and applications","author":"Boyde","year":"1986","journal-title":"Scan Electron Microsc"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI0217124","article-title":"Manipulating the environment of cancer cells in bone: A novel therapeutic approach","volume":"110","author":"Martin","year":"2002","journal-title":"J Clin Invest"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1677\/ERC-09-0012","article-title":"Mechanisms of bone metastases of breast cancer","volume":"16","author":"Suva","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1440-1711.1999.00815.x","article-title":"Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development","volume":"77","author":"Kong","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"10683","DOI":"10.3390\/ijms140610683","article-title":"RANK\/RANK-L\/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: A prospective study","volume":"14","author":"Mercatali","year":"2013","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:00:57Z","timestamp":1786647657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.179085","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}